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Purpose: To evaluate the role of in vivo dosimetry with radiochromic films for dose verification in cutaneous
radiation therapy (RT).
Methods: Five patients with 8 cutaneous or sub-cutaneous malignancies of the face, neck, trunk and extremity
receiving RT were included. Orthovoltage, megavoltage photon therapies were applied based on anatomic location.
The delivered dose for each target was measured with GAFCHROMIC EBT3TM film. The differences between the
prescribed and measured doses in each target were analyzed based on the RT characteristics, target location and
custom patient set up. The accuracy of EBT3TM film measurement was verified by measurements in a solid water
phantom.
Results: The mean measured dose was -3.2% (-9.6% to +2.3%, P=0.86) lower than prescribed over 23
measurements. A wide range of under dose was detected in orthovoltage therapy when a gap existed between
skin and a closed-ended applicator surface. The magnitude of the under dosage was correlated with the degree of
the gap (P=0.01). The phantom study confirmed the accuracy of GAFCHROMIC EBT3TM film measurement and
found that the low measured dose in orthovoltage therapy was caused by the deviation from the inverse square
law (ISL) of the beam output at extended source surface distance (SSD) for closed-ended applicators.
Conclusions: A significantly low delivered dose for extended SSD orthovoltage therapy was demonstrated during
cutaneous RT. The dose fall-off with distance is not completely compensated by the ISL standoff correction for
orthovoltage therapy. GAFCHROMIC EBT3™ film is a useful and accurate tool for quality assurance of patients
receiving a curative intended cutaneous RT.
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Quality assuranceIntroduction
Primary cutaneous malignancies mainly include basal
cell carcinoma (BBC) and squamous cell carcinoma
(SCC). BCC is usually slow growing, rarely metastasizes
and may be cured with effective local therapy including
surgical resection, radiation therapy (RT) or both [1-3].
RT for primary BCC has achieved local control rates of
80-100% [4-6]. RT is also commonly used for symptom
relief in metastatic cutaneous malignancies.* Correspondence: hongwei.liu@albertahealthservices.ca
1Central Alberta Cancer Center, 3942-50a Ave, Red Deer, AB T4N 6R2, Canada
2Department of Oncology, University of Alberta, Edmonton, AB, Canada
Full list of author information is available at the end of the article
© 2015 Liu et al.; licensee BioMed Central. Thi
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Orthovoltage X-rays or megavoltage (MV) energy elec-
trons are the main cutaneous radiotherapy tools [3,7,8].
MV photon therapy is used for large, subcutaneous tar-
gets with deep tissue involvement. Commonly, cutane-
ous RT is delivered with an appositional field using a
clinical set up and without 3D volumetric dose calcula-
tions. A percent depth dose curve is used to calculate
target dose coverage based on estimated tumor depth.
Compared to MV electron and photon treatments,
orthovoltage X-ray treatment units are relatively simple
with set-up reproducibility guided by the use of an appli-
cator (often called a “cone”) directly onto the target sur-
face. Orthovoltage beams deposit the maximal dose ats is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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electron and photon. A custom lead (Pb) cut-out can be
used to define irregularly shaped fields. However, some-
times there is a gap (standoff ) between the target surface
and the applicator. In such circumstances a standoff
correction using the inverse square law (ISL), is used to
account for the impact of dose fall-off due to distance
from the applicator end.
Accurate dose delivery is important to achieve and re-
port control rates during curative-intent cancer therapy. It
is possible that delivered dose may be different from the
estimated dose due to unanticipated or under-appreciated
skin gaps, tissue folds, or set-up and positioning
variation.
GAFCHROMIC EBT3™ film has an active layer of
radiation-sensitive organic microcrystal monomers on
thin polyester located between two identical polyester
layers. The film is near tissue equivalent. EBT3™ film is
highly sensitive to ionizing radiation. These features make
it potentially suitable as a pragmatic clinical dosimeter.
The aim of the current study was to examine the clinical
value of GAFCHROMIC EBT3™ film as an in vivo
dosimeter for quality assurance during cutaneous radio-
therapy. The manufacturer of GAFCHROMIC EBT3™ film
did not provide any funding or have any input into the
study design, conduct, analysis or reporting.
Materials and methods
Patients and targets
Five consecutive patients including one male and four
females received RT to 8 cutaneous or sub-cutaneous
lesions of the face, neck, trunk and extremity by a single
radiation oncologist. The median age was 86 years
(range 49–91 years). Skin lesions included primary BCC,
SCC and metastatic melanoma. This investigation was
considered a quality assurance study by the institutional
research ethics board but individual consent was ob-
tained from each patient prior to the film dosimetry
measurements.Table 1 Radiation therapy delivery parameters for the eight c
Target Pathology Field size App
Location (cm) (cm
Pre auricular BCC 3.0 3 ci
Medial canthus BCC 1.5 1.5
Nose tip BCC 1.5 × 1.5 1.5
Medial neck BCC 6 × 6 10 ×
Chest wall skin MM 3 × 3 3 ci
Chest wall skin MM 3 × 3 3 ci
Chest wall skin MM 5 × 6 6 ×
Left wrist SCC 7 × 6 -
SCC = Squamous cell carcinoma; BCC = Basal Cell Carcinoma; MM =Metastatic melanRadiation therapy
The RT dose was measured by placing film on the target
surface for patients who received orthovoltage X-ray
therapy. Additionally, one patient with MV photon ther-
apy was included for comparison. Patients with lesions
of the face, neck or chest wall skin were treated with
orthovoltage photons using an Xstrahl-300 X-ray ther-
apy unit (Xstrahl Ltd., Camberley, UK) with treatment
energies of 150 and 200 kVp and half-value layers of
6 mm Al and 1 mm of Cu, respectively. Treatment was
delivered with either open-ended circular applicators
(diameters of 1.5 or 3 cm) at 30 cm focus to skin surface
distance (FSD) for small lesions or closed-ended square
applicators at 50 cm FSD for larger lesions. Custom Pb
cut-outs were manufactured for large irregularly shaped
lesions treated with orthovoltage. One patient with a
SCC of the left wrist had a positive margin after amputa-
tion and received adjuvant RT with a single 6 × 7 cm2
field using 6 MV photons. A mould of the patient’s hand
and wrist was made out of Polyethylene Terephthalate
Glycol. The mould was mounted to a 10 × 22 × 30 cm3
plastic box filled with LiquiBlock™ to provide sufficient
backscattering and build-up for a 6 MV photon beam
LiquiBlock™ is a non-toxic absorbent polymer salt that
when mixed with water forms a jelly-like substance used
for bolus. The jelly was distributed so that 1–1.5 cm of
build-up covered the target area. A 101 cm source to skin
distance (SSD) was set to the skin surface. Table 1 presents
detailed information about the RT delivery parameters.
RT dose calculation and measurement
RT doses were prescribed, and film measurements were
taken at the skin surface. Monitor units (MUs) for
orthovoltage treatment were calculated based on the
prescribed daily dose modified by a back scatter factor
(BSF), ISL if there was standoff from the skin surface to
the applicator, and the machine output factor. The ISL
correction factor or standoff correction (SOF) factor was
defined as: I ISL = [FSDN/(FSDN + S)]
2 = SOF, where FSDNlinical lesions
licator size SSD Skin bolus Energy
) (cm) (cm)
rcle 30 0 150 kVp
circle 30 0 200 kVp
circle 30 0 150 kVp
10 50 0 200 kVp
rcle 30 0 200 kVp
rcle 30 0 200 kVp
6 50 0 200 kVp
101 1 6 MV
oma; kVp = orthovoltage energy; MV =Mega Volts.
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closed-ended applicators), and S is the amount of standoff
in cm. MUs for the MV photon treatment were calculated
using standard tissue-maximum ratios.
The delivered dose for each target was measured
with GAFCHROMIC EBT3™ film (International Specialty
Products, Wayne, NJ, USA) for a minimum of three frac-
tions per lesion (except one lesion had two). EBT3™ film
was placed on the skin surface. The goal was to measure a
point dose at the centre of the lesion. For each case, the
film was cut to conform to the lesion size and location. If
there was an irregular surface, the film was cut small
enough to be placed directly on the surface at the center
of the field. The smallest film was at least 1 × 1 cm2 and
the largest film was 6 × 6 cm2. Differences between pre-
scribed and measured doses were calculated as: (DoseM –
Dosep)/Dosep × 100%, where Dosep, and DoseM were the
planned and measured doses, respectively.
A single batch (Lot# A05151203) of EBT3™ film was
used for all measurements because the film response
and calibration curves can be batch specific [9]. Films
were stored in a light-proof container to minimize UV
contamination. The films were scanned with an Epson
Expression 10000XL flat-bed scanner (Epson America,
Inc. Long Beach, CA, model XL 10000). Based on scan-
ner uniformity (pixel value variation), dose calibration
curve fitting, and measurement reproducibility, it was
estimated that the film dosimetry protocol accuracy var-
ied by 3-5% for doses from 800 cGy down to 200 cGy.
Therefore, measured systematic dose deviations greater
than 5% warranted further investigation.Figure 1 Comparison of the prescribed dose with the EBT3™ film mea
therapy (N = 23).EBT3 film calibration, phantom measurements and ion
chamber dose verification
The calibration films were cut into 4 × 4 cm2 pieces. Due
to the energy dependence of EBT3 films from the kilovol-
tage range to the MV range [10], separate calibration
curves were calibrated for 150 kVp and 200 kVp beams,
and a 60Co unit (Theratron 780-C; Best Theratronics,
Ottawa, ON, Canada) was used to calibration for the MV
beam. The Xtrahl orthovoltage treatment beam was
calibrated in absolute dose following the American
Association of Physicists in Medicine (AAPM) TG61
guideline [11], and the 60Co unit was calibrated following
the AAPM TG51 guideline [12]. A minimum of two films
were used for each dose level of the calibration curve,
and the films are scanned in RGB color mode using only
the red color channel. This produced a calibration curve
of dose in cGy against net optical density. Film handling
and scanning protocol followed the procedure described
previously [10].
A systematic difference between measured and pre-
scribed dose was noticed for patients treated on orthovol-
tage in whom a standoff correction had been calculated
(Figures 1 and 2). To investigate the dose deviations
from the ISL estimates, the EBT3 film was placed on a
solid water phantom and the number of MUs required
to deliver a dose of 700 cGy with a 10 × 10 cm2 square,
closed-ended applicator with no standoff (i.e. 0 cm) was
delivered at 0, 1, 2, 3, and 5 cm standoff distances. The
same experiment was repeated with a Markus plane
parallel ionization chamber (PTW Frieburg, Germany;
model N23343) in air for verification. A detailedsured dose for MV photon, and orthovoltage X-ray radiation
Figure 2 Correlation of the dose difference measured with EBT3™ film with air gap (<5 mm, 4 sites; 5-10 mm 2 sites; >10 mm, 1 site)
during orthovoltage radiation therapy (P = 0.01).
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reported previously [13]. To directly compare the film
results from the phantom surface with the in air ion
chamber measurements, the field size dependent BSF
from AAPM TG61 were factored out to account for
phantom backscatter and increase in field size on theFigure 3 Relative dose fall-off with standoff using a 10 × 10 cm2 close
water phantom and compared to the expected fall-off based on the i
measurements for direct comparison with the in air ion chamber measurem
between ion chamber and film.water phantom due to beam divergence with increasing
standoff [11].
Statistical analysis
The mean differences between film-measured and pre-
scribed doses were compared using a two-tail Student’sd-ended applicator measured with EBT3 film placed on a solid
nverse square law. The BSF was factored out of the film
ents and the expected fall-off. Excellent agreement is demonstrated
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statistical significance. ANOVA was used to analyze the
differences between group means and their associated
variation.
Results
We evaluated over 23 measurements for 8 lesions. On
average the film measurements were 3.2% lower (−9.6%
to +2.3%, P = 0.86) than the prescribed doses (Figure 1).
For the 6 MV photon case, the measured dose was 3.2%
lower than prescribed (range, −4.9 to −0.6%). Doses
measured during orthovoltage treatments showed wide
deviations from the prescribed doses. A subgroup classi-
fication based on the ranges of gaps between the skin
surface and the end of the applicator cone (N = 20 obser-
vations) is presented in Figure 2. Under dosage of more
than 5% was detected when there was a gap of > 5 mm
between the skin and a closed-ended applicator surface.
Using ANOVA the degree of the under dosage was well-
correlated with the degree of the gap distance (P = 0.01).
The observed correlation between standoff and mea-
sured under dosage was investigated using water phantom
measurements. After factoring out the impact of back scat-
ter, the film measurements compared those measured with
an ion chamber were well within experimental uncertainty.
The dose fall-off with gap distance measured by the EBT3™
film was greater than predicted by the ISL standoff correc-
tion as shown in Figure 3. The physical set-up details and
investigations for the ion chamber measurements have
been reported in a separate publication [13].
Discussion
In the current study, film-measured dose during ortho-
voltage therapy displayed large deviations from calcu-
lated doses in particular, when there was standoff of
1 cm or greater. The Xstrahl-300 orthovoltage unit wasFigure 4 Illustration of the gap between skin and cone surface during
B. Closed-ended applicator with a gap in the clinical set up.commissioned for clinical beams of 100, 150, and 200 kVp
using a range treatment delivery device from 1.5 cm cir-
cles to 20 × 20 cm2 open-ended or closed-ended applica-
tors. The clinical decision to use a particular applicator is
based on tumor size, lesion depth and location. When an
air gap exists between the skin surface and the end of the
applicator, an ISL correction is used to adjust the number
of MUs delivered to compensate for beam divergence.
When the standoff gap was larger than 1 cm, the dose
measured with the EBT3™ film was significantly lower
than the prescribed dose and the extent of under dosage
was directly proportional to the size of the air gap between
the skin surface and the end of the treatment unit applica-
tor (Figure 2). Applying the traditional ISL correction for
the standoff did not fully compensate for the actual dose
drop.
A 1–2 cm air gap is most likely to occur when a
closed-ended applicator is applied to an irregular surface
(Figure 4). For larger tumors using a 50 cm FSD and a
closed-ended cone, parts of the field may experience
gaps of more than 1 cm. The convergence of measured
doses using EBT3 film on water phantoms compared to
in air ion chamber measurements confirms that the rela-
tive dose decline is a function of incomplete standoff
correction when using an ISL correction alone. Several
phantom studies have confirmed that EBT3™ film can be
used for quality assurance in a variety of radiotherapy
applications, including at orthovoltage energies [10,14,15]
but this is the first to report the discrepancy between film-
measured doses and ISL adjusted, prescribed doses for pa-
tients with air gaps of 1 cm or greater.
Previously [13], we quantified the deviation from the
ISL of closed-ended applicators using an orthovoltage
treatment unit, as has been reported by others [16,17].
The mechanism of the under dosage at extended SSD is
attributed to the endplate of closed-ended applicators.an orthovoltage delivery. A. Open-ended applicator with no gap vs.
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applicators act as an additional X-ray scatter source and
effectively reduce the effective FSD of the clinical ortho-
voltage beam. This causes a more rapid dose fall-off than
predicted by a basic ISL correction. The independent
phantom film study and ion chamber measurements
confirmed that the lower doses observed in the patient
measurements were reproducible and quantifiable [13].
The divergence between calculated and measured doses
became clinically significant when there was a large gap
between the skin surface and the closed-ended cone
even after an ISL correction was made because the ISL
correction does not account for end-plate scattering
[13]. Using only the inverse square law to account for a
gap more than 1 cm might result in an under estimated
dose of 5% or more.
The film measurements from 6 MV photon revealed
non-significant dose difference between estimated and
delivered. Therefore, no more case studies were further
performed. This was in line with our initial study objec-
tives of any systematic uncertainty greater than 5% war-
ranted further investigation. The concordance of doses
during the MV photon treatment in this study could
be considered an additional verification of the sys-
tematic variation noted between the film-measured and
prescribed doses when using orthovoltage energy with
closed end applicators with increasing applicator to skin
gaps.
Only small dose variations were observed between
fractions. This is attributed to variations in patient set-
up, reproducibility of skin lesion positions and uncer-
tainties in placement of the film dosimeter between
fractions. The current results suggest that a simple,
in vivo dosimeter should be part of treatment planning
quality assurance during curative intent cutaneous RT.
At the very least it should be used for initial treatments
on a new orthovoltage unit, and when there is measur-
able standoff between the applicator end plate and the
skin surface.
Cutaneous cancers occurring on irregular skin surfaces
such as the face, ear or neck are commonly seen in the
clinic. Orthovoltage RT provides a simple, non-invasive
alternative to surgical excision and can achieve high
rates of complete response and local control. For small
lesions encompassed in open-ended cones without air
gaps, calculated doses are reliable estimates of the
delivered dose. For larger lesions and lesions located on
irregular surfaces treated with closed-ended applicators,
a 1 cm or larger gap requires a larger correction than es-
timated using the ISL correction. For such cases, EBT3™
film-based in vivo dosimetry should be used as a quality
assurance tool that can help to assess dose delivery.
Minimization of large skin gaps is crucial to avoid un-
acceptable under dosage.Conclusion
EBT3™ film-based in vivo dosimetry demonstrated that
delivered doses were significantly lower than calculated
doses for extended SSD orthovoltage techniques using
closed-ended applicators. Dose fall-off due to air-gaps as
frequently occur when treating irregular surfaces were not
completely compensated by the inverse-square law correc-
tions. This is commonly neglected in clinical practice. In
vivo film measurements can be used to improve quality as-
surance during curative intent cutaneous radiotherapy.
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